Approval Of Un-Audited Financial Results For The 3rd Quarter & Nine Months Ended 31st December 2025 as attached.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved unaudited results for the third quarter and nine months ended 31 December 2025. Revenue from operations fell sharply to Rs. 1,057.93 lakhs in Q3 FY26 from Rs. 1,415.95 lakhs in Q3 FY25, a drop of about 25%. For the nine-month period, revenue declined to Rs. 3,743.87 lakhs from Rs. 5,310.62 lakhs, a fall of roughly 30%. Net profit for Q3 came in at Rs. 182.21 lakhs, down about 62% from Rs. 474.29 lakhs a year ago, while nine-month net profit dropped to Rs. 577.63 lakhs from Rs. 1,146.30 lakhs. The company operates in the Active Pharmaceutical Ingredients (APIs) segment, with exports of Rs. 3,390.55 lakhs making up the bulk of nine-month sales. The statutory auditors issued a clean limited review report with no qualifications.
The steep decline in both revenue and profits is a red flag and may weigh on the stock in the short term, as it indicates significant pressure on the company's core API business despite a clean audit review.